These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30254402)

  • 1. Biomarkers for hepatocellular carcinoma: What's new on the horizon?
    Ocker M
    World J Gastroenterol; 2018 Sep; 24(35):3974-3979. PubMed ID: 30254402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of next generation sequencing for matching advanced hepatocellular carcinoma patients to targeted and immunotherapy.
    Du J; Zhang E; Huang Z
    Front Immunol; 2024; 15():1358306. PubMed ID: 38665910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
    Sakai K; Takeda H; Nishijima N; Orito E; Joko K; Uchida Y; Izumi N; Nishio K; Osaki Y
    Oncotarget; 2015 Aug; 6(25):21636-44. PubMed ID: 26046304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma.
    Rastogi A
    World J Gastroenterol; 2018 Sep; 24(35):4000-4013. PubMed ID: 30254404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
    Neureiter D; Stintzing S; Kiesslich T; Ocker M
    World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
    Marisi G; Cucchetti A; Ulivi P; Canale M; Cabibbo G; Solaini L; Foschi FG; De Matteis S; Ercolani G; Valgiusti M; Frassineti GL; Scartozzi M; Casadei Gardini A
    World J Gastroenterol; 2018 Sep; 24(36):4152-4163. PubMed ID: 30271080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of liver biopsy in hepatocellular carcinoma.
    Di Tommaso L; Spadaccini M; Donadon M; Personeni N; Elamin A; Aghemo A; Lleo A
    World J Gastroenterol; 2019 Oct; 25(40):6041-6052. PubMed ID: 31686761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells.
    Qiu MJ; He XX; Bi NR; Wang MM; Xiong ZF; Yang SL
    Clin Chim Acta; 2018 Oct; 485():103-105. PubMed ID: 29940148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long non-coding RNAs in hepatocellular carcinoma: Potential roles and clinical implications.
    Niu ZS; Niu XJ; Wang WH
    World J Gastroenterol; 2017 Aug; 23(32):5860-5874. PubMed ID: 28932078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma.
    DeLeon TT; Ahn DH; Bogenberger JM; Anastasiadis PZ; Arora M; Ramanathan RK; Aqel BA; Vasmatzis G; Truty MJ; Oklu R; Bekaii-Saab TS; Borad MJ
    Future Oncol; 2018 Mar; 14(6):553-566. PubMed ID: 29460642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response.
    Burkhart RA; Ronnekleiv-Kelly SM; Pawlik TM
    Surg Oncol; 2017 Jun; 26(2):138-145. PubMed ID: 28577719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
    Liu J; Liu Y; Meng L; Liu K; Ji B
    Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next Generation of Preclinical Liver Cancer Models.
    Weber A; O'Connor T; Heikenwalder M
    Clin Cancer Res; 2015 Oct; 21(19):4254-6. PubMed ID: 26169964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers for response to immunotherapy in hepatobiliary malignancies.
    Lin ZF; Qin LX; Chen JH
    Hepatobiliary Pancreat Dis Int; 2022 Oct; 21(5):413-419. PubMed ID: 35973935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic heterogeneity: next-generation sequencing enables biomarker identification for hepatocellular carcinoma.
    Ziogas DE; Lykoudis EG; Roukos DH; Glantzounis GK
    Biomark Med; 2017 Jul; 11(7):515-518. PubMed ID: 28699774
    [No Abstract]   [Full Text] [Related]  

  • 17. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
    J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
    Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
    J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatocellular carcinoma: molecular pathogenesis and novel targets for therapy].
    Marquardt JU; Galle PR; Teufel A
    Dtsch Med Wochenschr; 2012 Apr; 137(16):855-60. PubMed ID: 22495921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in targeted therapies for hepatocellular carcinoma in the genomic era.
    Llovet JM; Villanueva A; Lachenmayer A; Finn RS
    Nat Rev Clin Oncol; 2015 Jul; 12(7):408-24. PubMed ID: 26054909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.